(MENAFN- Swissinfo) A new tool to evaluate kidney function developed by Swiss pharma firm Roche and which uses artificial intelligence has passed a regulatory test. The Chronic Kidney Disease algorithm panel has received the European CE marking of conformity, the Basel-based company announced on Monday. This content was published on October 6, 2025 - 14:41 2 minutes Keystone-SDA

• Italiano it Roche: via libera a test renale basato su intelligenza artificiale Original Read more: Roche: via libera a test renale basato su intelligenza artificial

+Get the most important news from Switzerland in your inbox

The new tool is designed to help assess the progression of kidney function loss. It can be used in patients diagnosed with chronic kidney disease and adults with diabetes or hypertension who are at high risk of reduced kidney function.

“Chronic kidney disease affects more than 700 million people worldwide and is widely recognised as a global health challenge,” Roche said in a statementExternal link .“With early diagnosis and appropriate treatment, it is possible to delay or prevent the decline in kidney function and reduce cardiovascular health risks, as well as related healthcare costs.”

More More Drug pricing How a clash with Roche exposed cracks in Swiss drug pricing system

This content was published on Sep 19, 2025 Switzerland's new process to speed up patient access to the latest drugs hit its first major hurdle in a clash with Roche.

Read more: How a clash with Roche exposed cracks in Swiss drug pricing syste

MENAFN06102025000210011054ID1110157433